

RESEARCH

Open Access



The effect of abscisic acid chronic treatment on neuroinflammatory markers and memory in a rat model of high-fat diet induced neuroinflammation

Sandra Sánchez-Sarasúa^{1†}, Salma Moustafa^{1†}, Álvaro García-Avilés¹, María Fernanda López-Climent², Aurelio Gómez-Cadenas², Francisco E. Olucha-Bordonau¹ and Ana M. Sánchez-Pérez^{1*}

Abstract

Background: Western diet and lifestyle are associated with overweight, obesity, and type 2 diabetes, which, in turn, are correlated with neuroinflammation processes. Exercise and a healthy diet are important in the prevention of these disorders. However, molecules inhibiting neuroinflammation might also be efficacious in the prevention and/or treatment of neurological disorders of inflammatory etiology. The abscisic acid (ABA) is a phytohormone involved in hydric-stress responses. This compound is not only found in plants but also in other organisms, including mammals. In rodents, ABA can play a beneficial role in the regulation of peripheral immune response and insulin action. Thus, we hypothesized that chronic ABA administration might exert a protective effect in a model of neuroinflammation induced by high-fat diet (HFD).

Methods: Male Wistar rats were fed with standard diet or HFD with or without ABA in the drinking water for 12 weeks. Glucose tolerance test and behavioral paradigms were performed to evaluate the peripheral and central effects of treatments. One-Way ANOVA was performed analyzed statistical differences between groups.

Results: The HFD induced insulin resistance peripherally and increased the levels of proinflammatory markers in the brain. We observed that ABA restored glucose tolerance in HFD-fed rats, as expected. In addition, chronic ABA treatment rescued cognitive performance in these animals, while not affecting control diet fed animals. Moreover, it counteracted the changes induced by HFD in the hypothalamus; microglia activations and TNF α mRNA levels.

Conclusion: These results suggest that ABA might become a new therapeutic molecule improving the neuroinflammatory status and insulin resistance.

Keywords: Obesity, Working memory, Microglia, Phytohormones

Background

Obesity, a leading cause of type 2 diabetes [1], correlates with cognitive impairment. Insulin sensitizers have been proposed as a promising tool for the reduction of obesity-induced insulin resistance and inflammation processes. The thiazolidinediones (TDZ) are a family of

synthetic insulin sensitizer molecules; however, some of them have undesirable side effects [2–4]. Thus, alternative compounds with analogous properties but fewer side effects are needed. The phytohormone abscisic acid (ABA) was found in mammalian cells more than 25 years ago [5]. Since then, several studies have proposed it as a universal signaling molecule [6, 7]. Structurally, ABA is very similar to the TDZs. Indeed, ABA can improve glucose tolerance [8], reduce the level of TNF α , and decrease adipocyte cell size in an *in vivo* model of obesity induced by HFD [9]. Moreover, in human and murine

* Correspondence: sanchean@uji.es

[†]Equal contributors

¹Department of Medicine, University of Jaume I, Vicente Sos Banyat s/n, 12071 Castellón de la Plana, Castellón, Spain

Full list of author information is available at the end of the article



pancreatic cell lines (RIN-m and INS-2 cells), ABA can increase glucose-stimulated insulin secretion [10]. This effect can be repressed using pertussis toxin and PKA inhibitors [11]. Dietary ABA also stimulates granulocyte function and macrophage infiltration in the adipose tissue [12]. In mammalian cells, the lanthionine synthetase C-like protein 2 (LANCL2) shows high homology with the ABA receptor in plants, the *Arabidopsis* GCR2. Silencing the expression of endogenous LANCL2 in granulocyte cells can abrogate ABA induction of Ca^{2+} responses, whereas overexpression of LANCL2 enhances the ABA-mediated effects [13]. Because of its role in the mediation of ABA effects, LANCL-2 has been proposed as a therapeutic target for the treatment of inflammatory diseases and diabetes [14].

Furthermore, ABA shows some molecular structural similarities to retinoic acid (RA). RA has beneficial cognitive effects, rectifying memory deficits in rodent models of Alzheimer disease. However, the clinical and animal model data show an association between RA administration and the symptoms of depression [15]. Chronic treatment with ABA has beneficial antidepressant effects demonstrated by increased sucrose intake, increased swimming in the forced swim test, and reduced expression of CRH and $\text{RAR}\alpha$ mRNA in the rat hypothalamus in control rats, with no reported side effects [16]. Moreover, preliminary data show an improved spatial memory in rats treated with ABA [17]. On the basis of these data, we hypothesized that as ABA can modulate peripheral insulin resistance and immune response, it might also exert similar action centrally. Thus, it this work aims to show whether dietary ABA could restore cognitive deficits resulting from a high fat diet (HFD) induced neuroinflammation. HFD elevates the levels of neuroinflammation markers in the brain [18] and it might constitute a link between obesity and degenerative disorders via insulin resistance [19]. Furthermore, HFD has been shown to induce memory loss through elevation of inflammatory markers in hippocampus [20].

We administered ABA (20 mg/L) in the drinking water to rats on either HFD or standard diet (SD). After eleven weeks of treatment, we compared the behavior of the four groups using two memory paradigms: the novel object recognition (NOR) and the T-maze. In addition, we

measured ABA levels in the blood and cerebellum of all four groups using HPLC. We analyzed the microglia proliferation using immunohistochemistry. We demonstrated that the ABA administered in drinking water improved glucose tolerance and cognitive performance and decreased the levels of inflammatory markers in the hypothalamic areas. Our results confirm a therapeutic potential of this phytohormone in the peripheral metabolic alterations. The data also strongly suggest the potential beneficial effects of ABA in disorders of neuroinflammatory etiology, which has not been demonstrated before.

Methods

The aim of the experiment is to evaluate the central effects of the phytohormone, ABA in a model of neuroinflammation elicited by HFD, during 12-week treatment. Behavioral tests started on the 11th week, and sacrifices were carried out in the 12th week of ABA and diet treatment (Fig. 1).

Animals and diet

Eight-week-old male Wistar rats were obtained from the Janvier Labs (Saint-Berthevin, France) and kept at the animal facility of the University Jaume I. The procedures followed the directive 86/609/EEC of the European Community on the protection of animals used for experimental and other scientific purposes. The experiments were approved by the Ethics Committee of the University Jaume I. The animals were maintained on a 12 h:12 h light–dark cycle and housed in pairs to reduce stress due to social isolation. Rats were divided randomly into four experimental groups: SD, control animals fed the standard rodent diet (Ssniff, Soest, Germany); SD-ABA, animals fed standard diet supplemented with ABA (Fernandez-Rapado, Spain) in the drinking water (20 mg/L); HFD, animals fed a high-fat diet (5736 kcal/kg, Ssniff) (Table 1); and HFD-ABA, animals fed high fat diet and ABA in drinking water (20 mg/L). We based our estimations in previous papers where ABA had been administered in the food pellet. Considering the daily food (20 g/day) and water average intake (50 mL/day), we estimated the amount of ABA per mL of drinking water, in order to doses in the same range as previous papers (100 mg/Kg) [21]. In Guri study, the period of ABA treatment was shorter (36 days)




Fig. 1 Experiment design. Behavioral tests started in the 11th week, and the animals were sacrificed in the 11th and 12th week

Table 1 Composition of high fat diet

Crude Nutrients	%	Additives	per kg
Crude protein	24.4	Vitamin A (IU)	15000
Crude fat	34.6	Vitamin D ₃ (IU)	1500
Crude fibre	6.0	Vitamin E (mg)	150
Crude ash	5.5	Vitamin K ₃ (mg)	20
Starch	0.1	Vitamin C (mg)	30
Sugar	9.4	Copper (mg)	12
Fat	60 kJ%		
Energy	21.6 MJ (or kcal) ME/kg		

than our study (12 weeks), therefore we considered that the ABA administration could be lowered (1 mg/day) to achieve optimal chronic effects. The four groups were fed *ad libitum* for 12 weeks. The HFD diet induces inflammatory effects in the peripheral tissues [21] and the brain [22]. The body weight and food and water intake were monitored twice a week per cage.

Novel object recognition (NOR)

Training chamber consisted of a black wooden box (81 × 61 × 52.3 cm). Rats were habituated to the testing environment for 30 min on two consecutive days. On the first day, the rats spent a 10-min habituation period in the experimental box, without objects. On the second day, each rat was placed in the box for the *familiarization* phase and allowed to explore two identical objects (heavy metallic jars). One group (easy task group) was left for 10 min, and the second group (difficult task group) was left to explore for 3 min. All the rats were then returned to their home cages for a 1-h intertrial interval. The box and objects were cleaned with a 30 % ethanol solution. In the *test* phase, the rats were returned to the box and allowed to explore a familiar and novel object for further 5 min (easy task group) or 3 min (difficult task group) [23]. Familiar and novel objects were alternated between left and right to prevent location predisposition. Both trial and test phases were recorded using a video tracking system (Smart 2.5.19, Panlab, Barcelona, Spain) for subsequent behavioral analysis. Exploration was defined as time spent sniffing within 1–4 cm of the object or touching it, always with the head oriented towards the object. Climbing over the object or running around it was not considered exploration.

T-maze

The T-maze was a three-arm maze; one arm (119.3 × 18.2 cm) was longer than the other two, which were identical (21.1 × 34.5 cm); the entire maze was placed above the floor. The longer arm was chosen as the start arm. The rats were habituated to the behavior room for 30 min. On the test day, the animals were allowed to

explore the maze for 5 min, with access to two of the three arms (the home or start arm and the familiar arm). The rat was then returned to its home cage for a 2-h intertrial interval (difficult task group) or 90-min intertrial (easy task group), during which the maze was cleaned with 30 % ethanol. The rat was then placed back in the maze; this time the animal had access to all arms for 5 min [24]. The number of entries to the novel arm and the time rat spent in each arm was recorded using a video tracking system (Smart 2.5.19).

Glucose tolerance test

Rats were fasted overnight, and a drop of blood was taken from the tail before (t = 0) and 30 min (t = 30) and 120 min (t = 120) after glucose administration (2 g/kg). Plasma glucose was measured using Glucomen LX Plus glucometer.

HPLC ABA measurements

ABA was analyzed in all four groups using LC/ESI-MSMS, essentially as described in [25], with slight modifications. Briefly, 1 g of frozen tissue was extracted in ultrapure water using a tissue homogenizer (Ultra-Turrax, Ika-Werke, Staufen, Germany) after spiking with 100 ng of *d*₆-ABA. After extraction and centrifugation, pH of the supernatant was adjusted to 3.0, and it was partitioned twice against diethyl-ether (Panreac, Barcelona, Spain). The organic layers were combined and evaporated in a centrifuge vacuum evaporator (Jouan, Saint-Herblain, France). The dry residue was then resuspended in water-methanol (9:1) solution, filtered and injected into a UPLC™ Acquity system (Waters, Milford, MA, USA). The analyte was then separated on a reversed phase UPLC C18 column (Nucleodur C18, 1.8 μm, 50 × 2.0 mm, Macherey-Nagel, Barcelona, Spain). The solvents were methanol and water supplemented with 0.01 % acetic acid, applied at a flow rate of 300 μL min⁻¹. ABA was quantified with a Quattro LC triple quadrupole mass spectrometer (Micromass, Waters, Manchester, UK) connected online to the output of the column through an orthogonal Z-spray electrospray ion source. Quantitation of this hormone was achieved by external calibration with known amounts of standards.

Immunocytochemistry (ICC)

Rats were anesthetized with an overdose of pentobarbital (120 mg/kg Eutanax, Fatro, Barcelona, Spain) and transcardially perfused with saline (0.9 %) followed by 4 % paraformaldehyde (PFA) fixative in 0.1 M phosphate buffer, pH 7.4. After the perfusion, the brains were removed from the skulls and postfixed overnight at 4 °C in PFA. Then, the brains were immersed in 30 % sucrose for 48 h for cryoprotection. Sliding Microtome Leica SM2010R (Leica Microsystems, Heidelberg, Germany)

was used to obtain 40- μm -thick coronal frozen sections. The brains were cut in rostrocaudal direction; six series of slices were collected from each brain and stored at $-20\text{ }^{\circ}\text{C}$ for analysis.

For Iba1 staining, we used a goat anti-Iba1 (Abcam, Cambridge, UK). Briefly, free-floating sections were rinsed twice in 0.05 M Tris-buffered saline (TBS, pH 8.0) and once in TBS with 0.2 % Triton X-100, at room temperature. Sections were incubated in 4 % normal donkey serum for 1 h to reduce nonspecific labeling. Afterward, the sections were incubated in the primary antibody solution diluted 1:500 in 0.01 M phosphate buffered saline (PBS) containing 2 % normal donkey serum, TBS with 0.2 % Triton X-100, and 2 % bovine serum albumin for 24 h at room temperature. After washing off the excess of the primary antibody, the sections were incubated in biotinylated donkey anti-goat secondary antibody (Jackson) (1:200 in TBS, 0.2 % Triton X-100). Two hours later, the sections were transferred to the avidin–biotin–horseradish peroxidase complex solution (Standard Elite ABC kit, Vector Laboratories Burlingame, CA USA) for 90 min, followed by two rinses with TBS with 0.2 % Triton X-100, and two more with 0.05 M Tris/HCl pH 8.0. Then, the sections were processed in 0.05 M Tris/HCl pH 8.0 containing 3.125 mg of DAB and 2 μL of H_2O_2 for 15–20 min. The reaction was stopped by adding an excess of 0.05 M Tris/HCl pH 8.0, followed by several rinses in PBS. Finally, the sections were mounted onto gelatin-coated slides, air-dried, dehydrated in alcohol, cleared in xylene, and cover-slipped with DPX mounting medium.

RNA extraction and RT-PCR


Total RNA was extracted from the hypothalamus ($n = 4$ –6 per group) using RNeasy Lipid Tissue Mini Kit (Qiagen, Valencia, CA, USA) according to the manufacturer's protocol. The RNA samples were resuspended in 50 μL of nuclease-free water. RNA concentration and quantification of total RNA was performed using Thermo Scientific NanoDrop 2000c, with the OD260/OD280. Genomic DNA was removed using DNase I, RNase-free (Life Technologies, USA), for 30 min at $37\text{ }^{\circ}\text{C}$. The reaction was stopped by addition of 1 μL of EDTA for 10 min at $65\text{ }^{\circ}\text{C}$. The first strand cDNA was synthesized using the PrimeScript™ RT Reagent Kit (Perfect Real Time) (Takara Bio Inc., Shiga Japan). For each reaction, 1 μg of RNA was used for reverse transcription, in a mixture of 4 μL of 5 \times PrimeScript Buffer; 1 μL of PrimeScript RT, 1 μL of Oligo dT Primer (50 μM), and 1 μL of random primer (100 μM). Enzyme mix was adjusted to a final volume of 20 μL at room temperature. The mixture was incubated at $37\text{ }^{\circ}\text{C}$ for 15 min and heated at $85\text{ }^{\circ}\text{C}$ for 15 min to terminate the reaction. The cDNA was subsequently stored at $-20\text{ }^{\circ}\text{C}$. RT-PCR was performed in a volume of

10 μL with 5 μL of Maxima SYBR Green/ROX qPCR Master Mix (2X) (Applied Biosystems Life Technologies, Carlsbad, CA, USA), 1 μL of primer and 1 μL of cDNA. All PCR reactions were performed under the following conditions: initial cycle at $98\text{ }^{\circ}\text{C}$ for 10 min followed by 40 cycles at $98\text{ }^{\circ}\text{C}$ for 10 s, $60\text{ }^{\circ}\text{C}$ for 10 s, and $72\text{ }^{\circ}\text{C}$ for 20s. Gene expression in the hypothalamus and hippocampus was quantified using a StepOnePlus Real-Time PCR system (Applied Biosystems Life Technologies). The RT-PCR primers for TNF α were Forward 5'GACCCTCACACTCAGATCATCTTCT3' and reverse 5'TGCTACGACGTGGGCTACG3'. Each sample was tested in triplicate. Data were analyzed using the comparative critical threshold method, with the amount of target gene normalized to the housekeeping gene β -actin. Relative gene expression was calculated using $2^{-\Delta\Delta\text{Ct}}$ relative to control.

Results

Animals were weighed, and water and food consumption was monitored twice a week. Behavioral tests started on the 11th week, and sacrifices were carried out in the 12th week of ABA and diet treatment (Fig. 1). As expected, overnutrition affected the body weight, but ABA administration did not affect the weight gain in either group. The results are presented as the means \pm SE ($n = 16$ per group). Control animals fed SD increased their body weight from 444 ± 11.7 g (week 1) to 585 ± 12.0 g (week 10). Similarly, animals on SD supplemented with ABA increased their body weight from 446 ± 10.7 g (week 1) to 593 ± 10.2 g (week 10). This represents an increment of 132 ± 2.4 % and 133 ± 1.5 %, for SD and SD with ABA, respectively. However, animals fed HFD and HFD-ABA increased their body weight from 448 ± 11.7 and 453 ± 12.2 g (week 1) to 659 ± 16.0 and 669 ± 16.2 g (week 10), an increase of 148 ± 3.2 % and 148 ± 2.8 %, respectively (Fig. 2a). Data were analyzed using a two-way ANOVA; time ($F_{(10,600)} = 994$, $p < 0.0001$) and diet ($F_{(3,60)} = 6.08$, $p = 0.001$) had a significant effect. Food and water consumption was measured per cage. Food intake data is represented by the mean (g) of food consumed \pm SE per cage each week ($n = 8$ per group). Weekly consumption was steady during the 12 weeks treatment, but the diet clearly affected food intake. The data were analyzed using two-way ANOVA ($F_{(3,28)} = 75.36$, $p < 0.0001$). To determine the ABA intake, we monitored weekly water consumption (Fig. 2c). Based on this information, we calculated ABA intake for both HFD and SD fed animals, and confirmed that both groups had a similar average weekly intake of the hormone, 12.30 ± 1.4 and 13.27 ± 0.8 mg/week/cage, respectively (Fig. 2d).

It has been reported that dietary ABA given in the food pellets (100 mg/kg food) can improve glucose tolerance [21]. To confirm that, in our model, ABA (20 mg/L of drinking water) improved the glucose homeostasis,



we performed a glucose tolerance test by intraperitoneal injection of glucose (2 mg/kg) in fasted animals. After 11 weeks of treatment, the animals fasted overnight (12–13 h). The basal glucose levels were similar in all groups; 30 min after glucose injection, blood glucose levels increased. No significant differences were observed between the groups. However, two hours after injection, glucose levels in HFD group remained higher (235.4 ± 36 mg/dL) than in HFD-ABA group (158.9 ± 11.23 mg/dL). In the latter group, the glucose levels were similar to those in control groups, SD (143.9 ± 10.24 mg/dL) and SD-ABA (152.6 ± 15.52 mg/dL). The data were analyzed using one-way ANOVA, with Newman–Keuls post-hoc test ($p < 0.05$) (Fig. 3).

HFD can induce memory impairments in rodents [26] and humans [27]. To examine the effect of chronic ABA administration on cognitive performance, the animals were subjected to two behavioral paradigms that evaluate the memory in rodents, NOR and T-maze test. NOR exploits the innate exploratory preference of novel objects exhibited by rodents. This paradigm examines the capability of the animal to remember a familiar object when presented with a new one. We observed no significant differences in the time spent exploring the identical objects during familiarization phase (Fig. 4a and c). During the test, all four groups spent much more time exploring the novel object than the familiar one, and neither the diet nor ABA treatment changed these parameters (Fig. 4b). However, we observed differences when both the familiarization time and test time were reduced to 3 min. In the HFD group, the times for

familiar and novel object did not differ significantly, suggesting impairment in remembering the familiar object. HFD-ABA animals behaved in the same way as the control groups (SD and SD-ABA), indicating that ABA could abrogate the HFD-induced impairment (Fig. 4d).

In the T-maze test, we recorded the number of entries to both maze arms, one of which was familiar and the other was novel because it had been closed during the habituation. We observed that rats fed SD, SD-ABA, and HFD-ABA had a significantly higher number of entries to the novel arm than to the familiar one. This was not the case for the animals fed HFD only, suggesting that this diet might impair the memory of the familiar arm (Fig. 5a). The data were analyzed using unpaired Student's *t*-test, comparing familiar and novel arm; $*p < 0.05 < **p < 0.01$. Interestingly, when the test was performed with a longer inter-trial time between familiarization and test phases, which may be a more difficult working memory task, HFD-ABA did not rescue the alternation behavior shown by the HFD group. We found that the difference between the number of entries to the two arms was no longer significant for HFD-ABA animals, in similarity with HFD group. Both SD and SD-ABA group maintained a significant difference in the exploratory behavior, entering the novel arm more often (Fig. 5b).

ABA levels in the blood and brain (cerebellum) were measured using HPLC. We detected variable amounts of circulating ABA in treated animals. However, we were unable to detect ABA under the same conditions in untreated animals, confirming that we, indeed, were observing exogenous ABA (Table 2). It has been




Fig. 3 The effect of dietary ABA (20 mg/L drinking water) on blood glucose levels in response to intraperitoneal (IP) glucose tolerance test. After 12 weeks of treatment, animals from the four groups were fasted overnight (12–13 h) and given 2 mg/kg of glucose by IP injection. Blood drops were taken from the tail, and plasma glucose concentration measured at the indicated times. Data are presented as the mean ± SEM. White circles represent rats fed HFD; black circles, HFD-ABA; white triangles, SD; and black triangles, SD-ABA. Data points at 120 min were analyzed using one-way ANOVA followed by post-hoc Newman–Keuls test. *, $p < 0.05$

reported that after intraperitoneal injections, ABA is widely distributed in the brain [17]. To ascertain that ABA crosses the blood–brain barrier in our model, we measured the ABA levels in the cerebellum as a sentinel. In similarity with the serum examination, ABA was only detected in the brains of treated animals (Table 2). Interestingly, only a very small proportion of circulating ABA crosses the blood–brain barrier. Thus, we confirmed that our method of ABA administration in drinking water was appropriate for measuring potential peripheral effects; the compound could cross the brain–blood barrier and might be responsible for the observed behavioral changes.

Next, we measured the levels of inflammatory markers in the brain. We used immunohistochemistry to detect the microglia-specific cytoplasmic marker Iba1 [28] in the hypothalamus (Fig. 6a). We observed that the number of microglial cells increased significantly in rat hypothalamus of HFD-fed rats (1613 ± 260.5 cells/mm²) in comparison with SD-fed controls (754 ± 135.2 cells/mm²). The ABA treatment reduced this effect in HFD animals (888 ± 158.8 cells/mm²) but did not affect SD-fed animals (794 ± 178.4





Fig. 4 Behavioral data for rats on a standard diet (horizontal lines, SD), high-fat diet (white columns, HFD), and supplemented with ABA in drinking water (20 mg/mL), HFD-ABA (diagonal lines) and SD-ABA (black columns) ($n = 8$). Novel Object Recognition data: time exploring two similar objects during familiarization phase (a, c) and time exploring familiar and novel object during test phase (b, d). Data is presented as mean ± SEM and analyzed using paired Student *t*-test, familiar vs. novel. ** $p < 0.01$; *** $p < 0.001$; ns, non-significant



cells/mm²) (Fig. 6b; one-way ANOVA, $p = 0.0135$). Representative images of microglia in the hypothalamus are shown in Fig. 6 (HFD, Fig. 6c; HFD-ABA, Fig. 6d; SD, Fig. 6e; and SD-ABA, Fig. 6f). In HFD group, apart from the increase in the number of Iba1-positive cells, the microglia cells were less ramified and more amoeboid than in controls, indicating an activated state (insets in images).

Next, we examined the levels of inflammatory and anti-inflammatory cytokines in the hypothalamus. The hypothalamus was dissected from all groups, and total RNA was isolated. Quantitative PCR was carried out to determine the expression levels of different cytokines.

We observed that TNF- α levels increased in the hypothalamus of HFD-fed rats in comparison with controls, confirming the existing reports [29, 30]. ABA administration restored TNF α levels to control values (Fig. 7). On the other hand, we found no significant differences in hippocampus, under the same conditions in all four groups (data not shown).

Discussion

Excessive energy intake is a major cause of obesity, which is recognized as one of the greatest threats to human health in the Western societies. Malfunction of hypothalamic neurons appears to underlie the pathology of metabolic diseases [31]. Even though the relationship between obesity (excess body fat) and neurodegeneration is highly complex, many sources link obesity and high fat consumption with certain neurodegenerative processes [19]. Growing evidence demonstrates that HFD induces insulin resistance, immunological and synaptic alterations in different brain areas [32, 33], and cognitive impairment [34].

In animal obesity models, the phytohormone ABA, related structurally to insulin sensitizers (TZDs) and memory-improvement molecules (such as retinoic acid), ameliorates the symptoms of type 2 diabetes. It targets PPAR- γ in a manner similar to the TZD class of antidiabetic drugs [21, 35]. In this study, we demonstrate, for the first time, that ABA can counteract some of the neurological effects (cognitive impairment and neuroinflammation markers) induced by HFD. We, in this study, and others have found that ABA can cross the blood brain barrier, but whether the improvement on cognitive functions is caused by direct action of ABA in brain, remains elusive.

Our protocol was designed to avoid an increase in behavioral anxiety. ABA was administered in the drinking water (20 mg/L) and not in food pellets since rats fed on an HFD tend to eat less than controls [36]. The dose was based on previous studies reporting dietary administration of ABA [21]. The vehicle used to dissolve ABA was added to water for SD and HFD groups to match any possible taste alterations. Some studies have used intraperitoneal injections (IP), which guarantee exact

Table 2 ABA quantification by HPLC. Cerebellum (A) and blood (B) were extracted from all four groups of treated animals

Cerebellum		Serum	
Diet group	ABA detected (ng/gr tissue)	Diet group	ABA detected (ng/gr plasma)
HFD	N.D	HFD	N.D
HFD-ABA	1.510 \pm 0.030	HFD-ABA	196.8 \pm 82.57
SD	N.D	SD	N.D
SD-ABA	2.980 \pm 0.100	SD-ABA	47.95 \pm 13.80

ND not detected

ABA was only detected in animals that had received exogenous administration of ABA in the drinking water (20 mg/L)




Fig. 6 Within the hypothalamus, ABA curtails the increase in microglia staining induced by high-fat diet (HFD). Map showing the location of the analyzed hypothalamus (a). Anterior (bregma -1.80 mm) and medial (bregma -3.12 mm) hypothalamus were used for quantification (b). HFD fed rats (c); HFD-ABA (d); standard diet, SD (e); and SD-ABA (f). Calibration bar, $200 \mu\text{m}$ (c–f). Data is represented as the mean \pm SEM of density of cells per mm^2 ($n = 6$). Data were analyzed using one-way ANOVA followed by post hoc Newman–Keuls test; *, $p < 0.05$ vs. HFD. The reactive microglia are shown in the insets at high magnification. Calibration bar, $50 \mu\text{m}$




Fig. 7 Cytokine mRNAs levels in the hypothalamus: proinflammatory cytokine TNF α in rats fed high fat diet (HFD, white columns); HFD supplemented with ABA in drinking water (20 mg/L) (HFD-ABA, diagonal lines); standard diet (SD, horizontal lines); and SD supplemented with ABA (SD-ABA, black columns). Data are presented as mean \pm SEM ($n = 4\text{--}6$ rats) and analyzed using one-way ANOVA followed by Newman–Keuls Multiple Comparison Test; *, $p < 0.05$ vs. HFD

dosing but are highly anxiogenic. Another innovation in our study was housing the animals in pairs to reduce stress due to isolation [37]. We considered these issues important since stress can affect feeding and cognitive behavior in many indirect ways [38]. Therefore, reducing the stress levels (by avoiding isolation and daily injections) was desirable. To examine the intake of ABA, we examined the average weekly water consumption in groups SD-ABA and HFD-ABA. Daily ABA intake was approximately $1.5\text{--}1.8 \text{ mg/kg}$. During the 12-week period, the intake average was uniform in all groups. To validate our strategy as an effective way of drug administration, we carried out a glucose tolerance test in all four groups. We confirmed that ABA improves glucose tolerance, reducing blood glucose levels to the normoglycemic range two hours after glucose injection.

The effect of specific diets on cognitive performance in rodents has been investigated using different behavioral

paradigms. Diets with increased sugar and fat content cause impairment in spatial and working memory [39–41] in both rats and mice. The link between obesity and inflammation of central nervous system is widely accepted; the hypothalamus is the area where inflammatory markers are most evident. Neuroinflammation underlies cognitive impairment [1]. However, some reports have suggested that ABA improves spatial memory [16]. ABA has anti-inflammatory and insulin-sensitizing properties, and there is some evidence suggesting that ABA is a PPAR γ agonist [42, 43]. Some reports have shown that PPAR γ agonism in the central nervous system ameliorates cognitive function [44, 45]. Therefore, we hypothesized that ABA would alleviate the HFD-induced neuroinflammation and cognitive defects. To follow up this assumption, we examined the performance of the rats in two simple memory tests, NOR and T-maze. In contrast to other reports, ABA did not significantly affect the animals fed a control diet. This discrepancy might have been caused by differences in animal handling. As mentioned above, we housed the animals in pairs to reduce the isolation anxiety and ABA was administered in the drinking water, reducing the IP injection-induced stress. Under these conditions, the reduced anxiety levels might have a positive effect on test performance. In the studies showing antidepressant-like effects of ABA, the compound has been administered daily using an IP injection [17]. We believe that in our model, the effect of ABA is independent of its antidepressant activity.

In an NOR working-memory test, all groups, including the HFD group, were able to discriminate between the novel and the familiar object. However, when the time spent in familiarization and test phases was shortened, thus reducing/hurting the acquisition phase, HFD-fed animals spent similar time exploring the novel and the familiar object. This indicated that they no longer remembered the familiar object. This behavior was efficiently counteracted by ABA treatment. ABA-treated animals behaved like the members of other groups, spending significantly more time exploring the novel object.

The alternation test (the T-maze test) is considered a reliable test to evaluate spatial working memory in rodents [46, 47]. Using this paradigm, we found that HFD could impair alternation; the animals had difficulties in remembering the previously visited arms. Chronic treatment with ABA can restore this capability. However, when the intervals between the tests were increased, making the task harder, HFD-ABA-fed animals no longer alternated, behaving like the animals in the HFD group. This indicated that they had lost the ability to discriminate between the familiar and novel arms. We would not attribute these differences to ABA metabolism, not only ABA is administered chronically, but during the intertrial interval rats have access to water and food. The peripheral anti-inflammatory effects ABA

are well known. However, to the best of our knowledge, there is no data on the effect of ABA on the cerebral immune response *in vivo*. Moreover, *in vitro* data are controversial; some studies show that ABA activates the microglia [48], whereas others report no effect [49]. Among the different types of glia, the resident macrophages in the brain, microglia, are responsible for cell debris clearance and release of cytokines that recruit other immunoresponsive cells to the central nervous system [50]. In the metabolic syndrome induced by HFD, microglia in the hypothalamus adopt a proinflammatory state, which is linked to an abnormal increase in the production of proinflammatory cytokines. These might be toxic to the neurons [51, 52]. In this study, we investigated the microglial expression in the hypothalamus in the four study groups. We examined the immunoreactivity of ionized calcium-binding adaptor molecule 1 (Iba1-ir), a cell marker upregulated during microglial activation [28]. In contrast to other studies of ABA effect on microglia *in vitro*, reporting either activation [46] or no effect [49], we demonstrated that *in vivo*, ABA reduces the number of Iba1-positive cells. This finding suggests an important practical application; the microglia hyperactivation has been found in a number of alterations including traumatic brain injury [53], cerebrovascular accidents [54], neurodegenerative disorders [55, 56], epilepsy [57], schizophrenia [58], and depression [59]. In addition, we analyzed Iba-1 expression in dorsal hippocampus, but, HFD did not increase microglia proliferation compared to control groups (data not shown).

Further to test the anti-inflammatory effects of ABA in the central nervous system, we measured the hypothalamic and hippocampal cytokine levels. The activated microglia synthesize and secrete proinflammatory cytokines, such as TNF α [60]. We observed an increase in TNF α levels in the hypothalamus of HFD-fed rats. ABA treatment rescued this effect, lowering TNF α to control levels. Contrary to other studies where inflammation markers have been found to increase in hippocampus, we found no significant difference in inflammatory markers TNF- α with HFD treatment compared to control groups. We postulate that not only hippocampal neuroinflammation underlies cognitive impairments.

Conclusion

In summary, we found that chronic treatment with ABA reduced HFD-induced microglia activation in hypothalamus, as revealed by Iba-1 staining. Also, TNF- α levels were altered in hypothalamus of HFD-fed animals, and these changes were counteracted by ABA administration. Moreover, ABA ameliorated the HFD-induced impairments in cognitive performance. We found no changes in neuroinflammatory markers in hypothalamus. In this study, we show that hypothalamic inflammation can

correlate with mild alterations in cognitive performance. Finally, based on our results, we conclude that ABA has a protective effect in neuroinflammation conditions, lowering microglia and TNF α levels and restoring cognitive function. Given the fact that ABA can cross the blood brain barrier; we postulate that this molecule could have a potential therapeutic value in the treatment of diseases of neuro-inflammatory etiology.

Abbreviations

ABA: Abscisic acid; ANOVA: Analysis of variance; CRH: Corticotropin releasing hormone; GCR: G-protein coupled receptor; HFD: High-fat diet; HPLC: High pressure liquid chromatography; ICC: Immunocytochemistry; LANCL2: Lanthionine synthetase C-like protein 2; NOR: Novel object recognition; PBS: Phosphate buffered saline; PFA: Paraformaldehyde; PPAR γ : Peroxisome proliferator-activated receptor gamma; RA: Retinoic acid receptor; RAR: Retinoic acid; RT-PCR: Real time-polymerase chain reaction; SD: Standard diet; TBS: Tris-buffered saline; TDZ: Thiazolidinediones; TNF- α : Tumor necrosis factor

Acknowledgements

The University of Jaume I has provided the entire infrastructure required.

Funding

This work was supported by Plan Propi Universitat Jaume I P1.1A2014-06 and GVA AICO/2015/042 to AMSP.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors' contributions

SSB and AGA carried out glucose tolerance tests, behavioral tests and ICC; SM carried out behavioral tests and RT-PCR; SSB, AGA and SM analyzed the data; MFLC did the ABA measurements. AG and FEOB contributed to the discussion. AMSP analyzed the data and wrote the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval

The procedures followed the directive 86/609/EEC of the European Community on the protection of animals used for experimental and other scientific purposes. The experiments were approved by the Ethics Committee of the University Jaume I and the government of "Generalitat Valenciana" according to European Union Guidelines. The number of the approved procedure is 2014/VSC/PEA/00209.

Author details

¹Department of Medicine, University of Jaume I, Vicente Sos Banyat s/n, 12071 Castellón de la Plana, Castellón, Spain. ²Department of Agriculture and Environmental Sciences, University of Jaume I, Vicente Sos Banyat s/n, 12071 Castellón de la Plana, Castellón, Spain.

Received: 22 August 2016 Accepted: 19 October 2016

Published online: 26 October 2016

References

- Miller AA, Spencer SJ. Obesity and neuroinflammation: a pathway to cognitive impairment. *Brain Behav Immun*. 2014;42:10–21.
- Della-Morte D, Palmirotta R, Rehni AK, Pastore D, Capuani B, Pacifici F, De Marchis ML, Dave KR, Bellia A, Fogliame G, Ferroni P, Donadel G, Cacciatore F, Abete P, Dong C, Pileggi A, Roselli M, Ricordi C, Sbraccia P, Guadagni F, Rundek T, Lauro D. Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors. *Pharmacogenomics*. 2014;15:2063–82.
- Panicker GK, Karnad DR, Salvi V, Kothari S. Cardiovascular risk of oral antidiabetic drugs: current evidence and regulatory requirements for new drugs. *J Assoc Physicians India*. 2012;60:56–61.
- Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. *N Engl J Med*. 2007;356:2457–71.
- Le Page-Degivry MT, Bidard JN, Rouvier E, Bulard C, Lazdunski M. Presence of abscisic acid, a phytohormone, in the mammalian brain. *Proc Natl Acad Sci U S A*. 1986;83:1155–8.
- Minorsky PV. Abscisic acid: a universal signalling factor? *Plant Physiol*. 2002;128:788–9.
- Gomez-Cadenas A, Vives V, Zandalinas SI, Manzi M, Sanchez-Perez AM, Perez-Clemente RM, Arbona V. Abscisic acid: a versatile phytohormone in plant signaling and beyond. *Curr Protein Pept Sci*. 2015;16:413–34.
- Magnone M, Ameri P, Salis A, Andraghetti G, Emionite L, Murialdo G, De Flora A, Zocchi E. Microgram amounts of abscisic acid in fruit extracts improve glucose tolerance and reduce insulinemia in rats and in humans. *FASEB J*. 2015;29:4783–93.
- Puce S, Basile G, Bavestrello G, Bruzzone S, Cerrano C, Giovine M, Arillo A, Zocchi E. Abscisic acid signaling through cyclic ADP-ribose in hydroid regeneration. *J Biol Chem*. 2004;279:39783–8.
- Bassaganya-Riera J, Skoneczka J, Kingston DGJ, Krishnan A, Misyak SA, Guri AJ, Pereira A, Carter AB, Minorsky P, Tumarkin R, Hontecillas R. Mechanisms of action and medicinal applications of abscisic Acid. *Curr Med Chem*. 2010;17:467–78.
- Bruzzone S, Bodrato N, Usai C, Guida L, Moreschi I, Nano R, Antonioli B, Fruscione F, Magnone M, Scarfi S, De Flora A, Zocchi E. Abscisic acid is an endogenous stimulator of insulin release from human pancreatic islets with cyclic ADP ribose as second messenger. *J Biol Chem*. 2008;283:32188–97.
- Guri AJ, Evans NP, Hontecillas R, Bassaganya-Riera J. T cell PPAR γ is required for the anti-inflammatory efficacy of abscisic acid against experimental IBD. *J Nutr Biochem*. 2011;22:812–9.
- Sturla L, Fresia C, Guida L, Bruzzone S, Scarfi S, Usai C, Fruscione F, Magnone M, Millo E, Basile G, Grozio A, Jacchetti E, Allegretti M, De Flora A, Zocchi E. LANCL2 is necessary for abscisic acid binding and signaling in human granulocytes and in rat insulinoma cells. *J Biol Chem*. 2009;284:28045–57.
- Lu P, Hontecillas R, Philipson CW, Bassaganya-Riera J. Lanthionine synthetase component C-like protein 2: a new drug target for inflammatory diseases and diabetes. *Curr Drug Targets*. 2014;15:565–72.
- Bremner JD, Shearer KD, McCaffery PJ. Retinoic acid and affective disorders: the evidence for an association. *J Clin Psychiatry*. 2012;73:37–50.
- Qi C-C, Zhang Z, Fang H, Liu J, Zhou N, Ge J-F, Chen F-H, Xiang C-B, Zhou J-N. Antidepressant effects of abscisic acid mediated by the downregulation of corticotrophin-releasing hormone gene expression in rats. *Int J Neuropsychopharmacol*. 2014;(1–9). doi:10.1093/ijnp/pyu006.
- Qi C-C, Ge J-F, Zhou J-N. Preliminary evidence that abscisic acid improves spatial memory in rats. *Physiol Behav*. 2015;139:231–9.
- Gao Y, Ottaway N, Schriever SC, Legutko B, García-Cáceres C, de la Fuente E, Mergen C, Bour S, Thaler JP, Seeley RJ, Filosa J, Stern JE, Perez-Tilve D, Schwartz MW, Tschöp MH, Yi C-X. Hormones and diet, but not body weight, control hypothalamic microglial activity. *Glia*. 2014;62:17–25.
- Spielman LJ, Little JP, Klegeris A. Inflammation and insulin/IGF-1 resistance as the possible link between obesity and neurodegeneration. *J Neuroimmunol*. 2014;273:8–21.
- Sobesky JL, Barrientos RM, De May HS, Thompson BM, Weber MD, Watkins LR, Maier SF. High-fat diet consumption disrupts memory and primes elevations in hippocampal IL-1 β , an effect that can be prevented with dietary reversal or IL-1 receptor antagonism. *Brain Behav Immun*. 2014;42:22–32.
- Guri AJ, Hontecillas R, Si H, Liu D, Bassaganya-Riera J. Dietary abscisic acid ameliorates glucose tolerance and obesity-related inflammation in db/db mice fed high-fat diets. *Clin Nutr*. 2007;26:107–16.
- Ropelle ER, Flores MB, Cintra DE, Rocha GZ, Pauli JR, Morari J, de Souza CT, Moraes JC, Prada PO, Guadagnini D, Marin RM, Oliveira AG, Augusto TM, Carvalho HF, Velloso LA, Saad MJA, Carvalheira JBC. IL-6 and IL-10 anti-inflammatory activity links exercise to hypothalamic insulin and leptin sensitivity through IKK β and ER stress inhibition. *PLoS Biol*. 2010;8(8). doi:10.1371/journal.pbio.1000465.
- Gaskin S, Tardif M, Cole E, Piterkin P, Kayello L, Mumby DG. Object familiarization and novel-object preference in rats. *Behav Processes*. 2010;83:61–71.

24. André C, Dinel A-L, Ferreira G, Layé S, Castanon N. Diet-induced obesity progressively alters cognition, anxiety-like behavior and lipopolysaccharide-induced depressive-like behavior: focus on brain indoleamine 2,3-dioxygenase activation. *Brain Behav Immun*. 2014;41:10–21.
25. Durgbanshi A, Arbona V, Pozo O, Miersch O, Sancho JV, Gómez-Cadenas A. Simultaneous determination of multiple phytohormones in plant extracts by liquid chromatography-electrospray tandem mass spectrometry. *J Agric Food Chem*. 2005;53:8437–42.
26. Cui Y, Shu Y, Zhu Y, Shi Y, Le G. High-fat diets impair spatial learning of mice in the Y-maze paradigm: ameliorative potential of α -lipoic acid. *J Med Food*. 2012;15:713–7.
27. Edwards LM, Murray AJ, Holloway CJ, Carter EE, Kemp GJ, Codreanu I, Brooker H, Tyler DJ, Robbins PA, Clarke K. Short-term consumption of a high-fat diet impairs whole-body efficiency and cognitive function in sedentary men. *FASEB J*. 2011;25:1088–96.
28. Ito D, Imai Y, Ohsawa K, Nakajima K, Fukuuchi Y, Kohsaka S. Microglia-specific localisation of a novel calcium binding protein, Iba1. *Brain Res Mol Brain Res*. 1998;57:1–9.
29. De Souza CT, Araujo EP, Bordin S, Ashimine R, Zollner RL, Boschero AC, Saad MJA, Velloso LA. Consumption of a fat-rich diet activates a proinflammatory response and induces insulin resistance in the hypothalamus. *Endocrinology*. 2005;146:4192–9.
30. Wang X, Ge A, Cheng M, Guo F, Zhao M, Zhou X, Liu L, Yang N. Increased hypothalamic inflammation associated with the susceptibility to obesity in rats exposed to high-fat diet. *Exp Diabetes Res*. 2012;2012:847246.
31. Velloso LA, Schwartz MW. Altered hypothalamic function in diet-induced obesity. *Int J Obes (Lond)*. 2011;35:1455–65.
32. Liu Z, Patil IY, Jiang T, Sancheti H, Walsh JP, Stiles BL, Yin F, Cadenas E. High-fat diet induces hepatic insulin resistance and impairment of synaptic plasticity. *PLoS One*. 2015;10:e0128274.
33. Petrov D, Pedrós I, Artiach G, Sureda FX, Barroso E, Pallàs M, Casadesús G, Beas-Zarate C, Carro E, Ferrer I, Vazquez-Carrera M, Folch J, Camins A. High-fat diet-induced deregulation of hippocampal insulin signaling and mitochondrial homeostasis deficiencies contribute to Alzheimer disease pathology in rodents. *Biochim Biophys Acta*. 1852;2015:1687–99.
34. Magnusson KR, Hauck L, Jeffrey BM, Elias V, Humphrey A, Nath R, Perrone A, Bermudez LE. Relationships between diet-related changes in the gut microbiome and cognitive flexibility. *Neuroscience*. 2015;300:128–40.
35. Guri AJ, Hontecillas R, Ferrer G, Casagran O, Wankhade U, Noble AM, Eizirik DL, Ortis F, Cnop M, Liu D, Si H, Bassaganya-Riera J. Loss of PPAR gamma in immune cells impairs the ability of abscisic acid to improve insulin sensitivity by suppressing monocyte chemoattractant protein-1 expression and macrophage infiltration into white adipose tissue. *J Nutr Biochem*. 2008;19:216–28.
36. Kamara K, Eskay R, Castonguay T. High-fat diets and stress responsivity. *Physiol Behav*. 1998;64:1–6.
37. Cruces J, Venero C, Pereda-Pérez I, De la Fuente M. A higher anxiety state in old rats after social isolation is associated to an impairment of the immune response. *J Neuroimmunol*. 2014;277:18–25.
38. Turner PV, Pekow C, Vasbinder MA, Brabb T. Administration of substances to laboratory animals: equipment considerations, vehicle selection, and solute preparation. *J Am Assoc Lab Anim Sci*. 2011;50:614–27.
39. McNeilly AD, Williamson R, Sutherland C, Balfour DJK, Stewart CA. High fat feeding promotes simultaneous decline in insulin sensitivity and cognitive performance in a delayed matching and non-matching to position task. *Behav Brain Res*. 2011;217:134–41.
40. McNay EC, Ong CT, McCrimmon RJ, Cresswell J, Bogan JS, Sherwin RS. Hippocampal memory processes are modulated by insulin and high-fat-induced insulin resistance. *Neurobiol Learn Mem*. 2010;93:546–53.
41. Valladolí-Acebes I, Stucchi P, Cano V, Fernández-Alfonso MS, Merino B, Gil-Ortega M, Fole A, Morales L, Ruiz-Gayo M, Del Olmo N. High-fat diets impair spatial learning in the radial-arm maze in mice. *Neurobiol Learn Mem*. 2011;95:80–5.
42. Bassaganya-Riera J, Guri AJ, Lu P, Climent M, Carbo A, Sobral BW, Horne WT, Lewis SN, Bevan DR, Hontecillas R. Abscisic acid regulates inflammation via ligand-binding domain-independent activation of peroxisome proliferator-activated receptor gamma. *J Biol Chem*. 2011;286:2504–16.
43. Bassaganya-Riera J, Guri AJ, Hontecillas R. Treatment of obesity-related complications with novel classes of naturally occurring PPAR agonists. *J Obes*. 2011;2011:897894.
44. Kariharan T, Nanayakkara G, Parameshwaran K, Bagasrawala I, Ahuja M, Abdel-Rahman E, Amin AT, Dhanasekaran M, Suppiramaniam V, Amin RH. Central activation of PPAR-gamma ameliorates diabetes induced cognitive dysfunction and improves BDNF expression. *Neurobiol Aging*. 2015;36:1451–61.
45. Nenov MN, Tempia F, Denner L, Dineley KT, Laezza F. Impaired firing properties of dentate granule neurons in an Alzheimer's disease animal model are rescued by PPAR γ agonism. *J Neurophysiol*. 2015;113:1712–26.
46. Olton D, Markowska A, Voytko ML, Givens B, Gorman L, Wenk G. Basal forebrain cholinergic system: a functional analysis. *Adv Exp Med Biol*. 1991;295:353–72.
47. DEMBER WN, FOWLER H. Spontaneous alternation behavior. *Psychol Bull*. 1958;55:412–28.
48. Bodrato N, Franco L, Fresia C, Guida L, Usai C, Salis A, Moreschi I, Ferraris C, Verderio C, Basile G, Bruzzone S, Scarfi S, De Flora A, Zocchi E. Abscisic acid activates the murine microglial cell line N9 through the second messenger cyclic ADP-ribose. *J Biol Chem*. 2009;284:14777–87.
49. Jiang SX, Benson CL, Zaharia LI, Abrams SR, Hou ST. Abscisic acid does not evoke calcium influx in murine primary microglia and immortalised murine microglial BV-2 and N9 cells. *Biochem Biophys Res Commun*. 2010;401:435–9.
50. Neumann H, Kotter MR, Franklin RJM. Debris clearance by microglia: an essential link between degeneration and regeneration. *Brain*. 2009;132(Pt 2):288–95.
51. Smith JA, Das A, Ray SK, Banik NL. Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases. *Brain Res Bull*. 2012;87:10–20.
52. Thaler JP, Yi C-X, Schur EA, Guyenet SJ, Hwang BH, Dietrich MO, Zhao X, Sarruf DA, Izgur V, Maravilla KR, Nguyen HT, Fischer JD, Matsen ME, Wisse BE, Morton GJ, Horvath TL, Baskin DG, Tschöp MH, Schwartz MW. Obesity is associated with hypothalamic injury in rodents and humans. *J Clin Invest*. 2012;122:153–62.
53. Lozano D, Gonzales-Portillo GS, Acosta S, de la Pena I, Tajiri N, Kaneko Y, Borlongan CV. Neuroinflammatory responses to traumatic brain injury: etiology, clinical consequences, and therapeutic opportunities. *Neuropsychiatr Dis Treat*. 2015;11:97–106.
54. Madinier A, Bertrand N, Mossiat C, Prigent-Tessier A, Beley A, Marie C, Garnier P. Microglial involvement in neuroplastic changes following focal brain ischemia in rats. *PLoS One*. 2009;4:e8101.
55. Bouvier DS, Murai KK. Synergistic actions of microglia and astrocytes in the progression of Alzheimer's disease. *J Alzheimers Dis*. 2015;45:1001–14.
56. Perry VH, Holmes C. Microglial priming in neurodegenerative disease. *Nat Rev Neurol*. 2014;10:217–24.
57. Riaz K, Galic M a, Kuzmiski JB, Ho W, Sharkey K a, Pittman QJ. Microglial activation and TNF α production mediate altered CNS excitability following peripheral inflammation. *Proc Natl Acad Sci U S A*. 2008;105:17151–6.
58. Najjar S, Pearlman DM. Neuroinflammation and white matter pathology in schizophrenia: systematic review. *Schizophr Res*. 2015;161:102–12.
59. Rial D, Lemos C, Pinheiro H, Duarte JM, Gonçalves FQ, Real JI, Prediger RD, Gonçalves N, Gomes CA, Canas PM, Agostinho P, Cunha RA. Depression as a glial-based synaptic dysfunction. *Front Cell Neurosci*. 2015;9:521.
60. McLarnon JG. Microglial chemotactic signaling factors in Alzheimer's disease. *Am J Neurodegener Dis*. 2012;1:199–204.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

